Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.58 |
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.42 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.42 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.93 |
| ▸ | MEN1 | O00255 | 4/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL504482 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29378721 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29497777 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL874057 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL94882 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL30078382 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28836366 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1646515 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9355084 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL866164 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117448328-A | VDAC2 inhibitor, application thereof and medicament for improving testis function | 南昌大学 | 2024-01-26 | — | — | CN | disclosed |
| WO-2022114163-A1 | HER2 TARGETING AGENT | 小野薬品工業株式会社 | 2022-06-02 | — | — | WO | disclosed |
| US-20220054573-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SANDALWOOD BIOTECH INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20210293786-A1 | Method Relating to Evaluation of Tumor Tissue of Experimental Animal | Konica Minolta, Inc. (JP) | 2021-09-23 | — | — | US | disclosed |
| EP-3477304-A1 | METHOD RELATING TO EVALUATION OF TUMOR TISSUE OF EXPERIMENTAL ANIMAL | Konica Minolta, Inc. (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-3106466-B1 | PEPTIDE, MAGNETIC PEPTIDE AND METHOD FOR DETECTING CELIAC DISEASE | UNIV AUTòNOMA DE BARCELONA (ES) | 2019-04-10 | — | — | EP | disclosed |
| EP-2044120-B1 | ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME | BIOALLIANCE CV (NL) | 2019-01-30 | — | — | EP | disclosed |
| US-10156565-B2 | Peptide, magnetic peptide and method for detecting celiac disease | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2018-12-18 | — | — | US | disclosed |
| US-10086112-B2 | Implant comprising FGF-18 | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20180238895-A1 | ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME | ALTRUBIO INC. | 2018-08-23 | — | — | US | disclosed |
| WO-1999026649-A1 | METHODS AND COMPOSITIONS FOR INHIBITING HIV INFECTIVITY AND BLOCKING CHEMOKINE ACTIVITY | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0852585-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) PROTEIN PRODUCT | AMGEN INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5731284-A | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product | AMGEN INC. (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997011965-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) PROTEIN PRODUCT | AMGEN INC. (US) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996005319-A1 | GENETICALLY ENGINEERED CELLS THAT PRODUCE DOPAMINE | ARCH DEVELOPMENT CORPORATION (US) | 1996-02-22 | — | — | WO | disclosed |
| US-5443859-A | Reacting tetracarboxylic acid dianhydride, aromatic diamine, optionally polyamine, to form polyamic acid, forming film, imidizing to form polyimide, carbonizing in inert gas or vacuum to form carbon film with specifed properties | TOHO RAYON CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| US-5438105-A | Polyamic acid has three dimensional network structure; other polymer component dispersed in network structure of the polyamic acid, and having chains interpenetrated with chains of polyamic acid; heat resistance, high strength | TOHO RAYON CO., LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| US-5352524-A | The carbon fiber sheet is derived from a polyimides of polyamic acid; tensile strength, electroconductivity, elasticity | TOHO RAYON CO., LTD. (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0454158-A1 | Polyamic acid composite, polyimide composite and processes for producing the same | Toho Rayon Co., Ltd. (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4275031-A | A CUVETTE WITH REAGENT EMBEDDED IN A CLEAR POLYMER COATING | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10156565-B2 | Peptide, magnetic peptide and method for detecting celiac disease | VIP, HAMP, PEPD | KCNH2 3330/4885CYP19A1 4462/4885GAA 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.